Trials

The effect of low-dose radiotherapy on pain in early osteoarthritis of the hip

Clinically node negative breast cancer patients undergoing breast conserving therapy: sentinel lymph node procedure versus follow-up

Neo-adjuvant chemotherapy followed by surgery vs. neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer

Influence of the intestinal microbiome on the outcome of treatment with preoperative chemoradiotherapy in patients with resectable oesophageal carcinoma

Prospective data collection initiative on colorectal cancer

National registration of patients with liver metastases treated with stereotactic body radation therapy.

Rectal preserving treatment for early rectal cancer. A multi-centered randomised trial of radical surgery versus adjuvant radiotherapy after local excision for early rectal cancers.

External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer

Randomised Phase III Trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy for women with early stage endometrial cancer

A nurse-led sexual rehabilitation programme for women with gynaecological cancers receiving radiotherapy: a randomized multicentre trial

Investigating the content, discrimination en convergence validity of the FACE-Q HNC questionaire

Evaluation of the impact of a decision aid tool for patients with advanced larynx cancer and assessment of its influence on shared decision making.

A phase 3 study to compare Nivolumab plus CCRT followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT followed by Nivolumab vs CCRT followed by Durvalumab in previously untreated, locally advanced non-small cell lung cancer.

Treating oligometastases with immune therapy, chemotherapy and radiotherapy, followed by definitive treatment of the primary tumour in patients with synchronous oligometastatic non small cell lung cancer.

Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment  on the oPtimal Treatment strategy

It is a multicentre, randomised, controlled open-label phase II clinical trial testing the hypothesis that a combination of (SAB)R and immunocytokineL19-IL2 increases the progression-freesurvival in patients with limited metastatic NSCLC. After randomisation by minimization, patients will be assigned either to the experimental arm (E-arm) or tothe control arm(C-arm).

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

An open label randomized exploratory study. Patients with early stage (T1cN0, T2aN0 and T2bN0) peripherally located NCSLC, eligible for surgical resection will be randomized between SBRT, SBRT with pembrolizumab or pembrolizumab monotherapy as induction regimen.

Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic, but it should be a lesion that increased in size, i.e. containing resistant cells, according to RECIST 1.1 criteria. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS) are allowed if these are standard for a certain location or palliative indication in the body.

A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

Ependymoma in Adults, Evaluation and Treatment Protocol

Primary intracranial germ-cell tumours in adults; evaluation and treatment protocol

The hypothesis of this study is that 6 fractions of high-precision, hypofractionated radiotherapy delivered with a higher dose per fraction is non-inferior to the standard fractionation schema and is associated with better quality of life and lower costs.

It will establish whether early adjuvant treatment with radiotherapy and adjuvant temozolomide in resected IDHmutated astrocytoma will improve outcome, and whether benefits of early treatment outweigh potential side-effects compared to active surveillance.

Medulloblastoma in Adults Treatment Protocol, Dutch Society for Neuro-Oncology (LWNO)

Evaluation methods to assess cognitive function and predict cognitive decline after treatment of meningioma are urgently needed. In this study, patients will undergo extensive cognitive testing combined with advanced brain MRI scans.

No standard re-radiation regimen has been defined for patients with recurrent glioma. In this study we determine if re-irradiation in 4 fractions is non-inferior to 10 fractions in the primary endpoint of survival after re-irradiation.

Metastases free progression free survival in prostate cancer patients with recurrent disease (< 5 metastases) treated with radiotherapy versus radiotherapy + 6 months ADT. A multicentre, randomized study.

A randomized study between whole gland prostate brachytherapy (control arm) and hemigland prostate brachytherapy (experimental arm). The study population consists of patients with proven unilateral significant adenocarcinoma of the prostate.

Prostate cancer Immune profiling before, during and after HDR-brachytherapy in local relapsed prostate cancer.

The impact of the implementation of a decision aid tool for prostate cancer patients on the decision making process

Demonstrate that the ProSpace is safe and effective in reducing the volume of the rectum receiving radiation in prostate cancer patients.